Deutsche Bank AG Buys 713 Shares of Medpace Holdings, Inc. $MEDP

Key Points

• Deutsche Bank AG has increased its stake in Medpace Holdings, Inc. by 11.5%, acquiring an additional 713 shares and bringing its total holdings to 6,927 shares valued at approximately $2.1 million.
• Medpace reported a quarterly EPS of $3.10, beating estimates, with revenues of $603.31 million, marking a 14.2% increase compared to the previous year.
• Institutional investors now hold 77.98% of Medpace's stock, illustrating strong interest among major investors in the company's performance.

Deutsche Bank AG increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 11.5% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,927 shares of the company's stock after acquiring an additional 713 shares during the quarter. Deutsche Bank AG's holdings in Medpace were worth $2,111,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Barclays PLC grew its position in Medpace by 42.4% in the 4th quarter. Barclays PLC now owns 28,166 shares of the company's stock valued at $9,359,000 after purchasing an additional 8,385 shares during the period. Mariner LLC boosted its holdings in Medpace by 42.3% during the 4th quarter. Mariner LLC now owns 2,825 shares of the company's stock worth $939,000 after acquiring an additional 840 shares during the last quarter. Marshall Wace LLP purchased a new position in Medpace during the 4th quarter worth $4,795,000. Commerce Bank boosted its holdings in Medpace by 15.9% during the 4th quarter. Commerce Bank now owns 2,058 shares of the company's stock worth $684,000 after acquiring an additional 283 shares during the last quarter. Finally, GeoWealth Management LLC boosted its holdings in Medpace by 27.8% during the 4th quarter. GeoWealth Management LLC now owns 285 shares of the company's stock worth $95,000 after acquiring an additional 62 shares during the last quarter. Institutional investors own 77.98% of the company's stock.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $465.72 on Thursday. The company's 50-day moving average is $372.56 and its 200 day moving average is $333.62. The company has a market capitalization of $13.08 billion, a P/E ratio of 34.63, a price-to-earnings-growth ratio of 2.91 and a beta of 1.42. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $501.30.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating the consensus estimate of $3.00 by $0.10. The business had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The company's revenue was up 14.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Insider Transactions at Medpace

In other news, General Counsel Stephen P. Ewald sold 3,000 shares of the stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $450.00, for a total value of $1,350,000.00. Following the sale, the general counsel directly owned 10,343 shares of the company's stock, valued at approximately $4,654,350. This represents a 22.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Kevin M. Brady sold 12,000 shares of the firm's stock in a transaction that occurred on Thursday, July 24th. The shares were sold at an average price of $454.23, for a total transaction of $5,450,760.00. Following the completion of the sale, the chief financial officer directly owned 6,000 shares in the company, valued at $2,725,380. This represents a 66.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 112,788 shares of company stock valued at $51,018,354. Company insiders own 20.30% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on MEDP. Truist Financial lifted their price objective on shares of Medpace from $298.00 to $436.00 and gave the stock a "hold" rating in a report on Wednesday, July 23rd. Cowen downgraded shares of Medpace from a "buy" rating to a "sell" rating in a report on Wednesday, July 23rd. William Blair reaffirmed a "market perform" rating on shares of Medpace in a report on Wednesday, July 23rd. UBS Group downgraded shares of Medpace from a "neutral" rating to a "sell" rating and lifted their price objective for the stock from $300.00 to $305.00 in a report on Tuesday, July 29th. Finally, Barclays lifted their price objective on shares of Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 23rd. Two equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, Medpace currently has a consensus rating of "Reduce" and a consensus target price of $406.60.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.